Biomarker shows potential to predict immunotherapy benefit for breast cancer patients
Biomarker shows potential to predict immunotherapy benefit for breast cancer patients A biomarker that has proven to be a predictor for response to immunotherapies in melanoma patients also has clinical relevance for breast cancer patients, according to a new study published in Clinical Cancer Research, a journal of the American Association for Cancer Research. The study demonstrated that this biomarker, a molecule called the Major Histocompatibility Complex Class II protein (MHC-II), has the potential to be a predictor of immunotherapy benefit with two types of breast cancer -- early-stage,...
Source: news-medical.net